Chronic total occlusions, a true challenge

Original title: Procedural Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention. A Report From the NCDR (National Cardiovascular Data Registry). Reference: Emanuel S. Brilakis, et al. JACC Cardiovascular Intervention 2015;8:245-53

Chronic total occlusions (CTO) are present in 20% to 50% of pathological coronary angiograms but, even though this percentage has increased in the past years, PCI is performed in around 4% of this kind of lesions.

This study included 594,510 stable patients; 22,365 of them (3.8%) received CTO PCI. Patients presenting CTO were younger, more frequently men, often with prior infarction, prior PCI and ventricular failure.

Procedural success was lower for CTO (59% vs. 96%; p<0.001), with marked variability in centers and operators. Procedural success was associated to the annual volume of CTO PCIs of operators, 10 being 53%, 62% and 75% (p<0.001). The group requiring vessel revascularization required greater contrast volume and longer fluoroscopy time.

Procedural success also increased with operator experience, 55.5% in 2009 to 61.9% in 2013 (p<0.01). Multivariable analysis associated lower procedural success to age, smoking, previous myocardial infarction, previous CABG, previous peripheral heart disease, right coronary artery CTO target vessel and less operator experience.

Combined events resulted higher in CTO PCIs than in conventional PCIs (1.6% vs. 0.8% p<0.001). More operator experience was associated to a lower events risk.

Conclusion

CTO PCI is not frequent in USA in stable patients and is associated to a lower procedural success and a higher complications rate, compared to outcomes in patients that do not present CTO. Success is associated with patient characteristics and operator experience.

Editorial Comment

When performing CTI success will depend on operator and center. Different studies have shown the benefits of revascularization, especially when it comes to the anterior descending artery.

Courtesy of Dr. Carlos Fava
Interventional Cardiologist
Favaloro Foundation– Argentina

Carlos Fava

Previous article
Next article

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....